Fryns-Aftimos Syndrome

Fryns-Aftimos syndrome (FA) is a very rare genetic condition that affects how the brain and face form before birth. Most current experts group FA within Baraitser–Winter cerebrofrontofacial syndrome (BWCFF), which is caused by single-letter (“missense”) changes in the ACTB (β-actin) or ACTG1 (γ-actin) genes. These genes make actin proteins that help cells move, divide, and build the brain’s outer layer (cortex). People can have wide-set eyes, droopy eyelids, a broad nasal bridge, eye coloboma, seizures, brain “pachygyria” (thick, simplified folds), hearing loss, short stature, and varied learning and movement difficulties. Many cases arise de novo (the first time in a family), but once present, the condition is autosomal dominant. There is no single cure; care focuses on seizures, vision/hearing, movement, feeding, development, and family support. Nature+3Nature+3NCBI+3

Researchers found that several individuals once labeled “Fryns-Aftimos” actually carry ACTB variants and fit severe Baraitser–Winter presentations. That’s why modern sources often treat FA as part of the BWCFF spectrum, not as a separate disorder. Diagnosis? usually uses exome/panel sequencing of ACTB/ACTG1 and careful clinical review. Nature+1

People with this condition can have different levels of severity. Some have significant brain malformations such as pachygyria (the brain surface has fewer folds), and others have milder changes. Hearing loss, short stature, muscle thinning around the shoulders, joint stiffness?, and heart or kidney differences may also occur. Because actin proteins are used all over the body, many organs can be involved. MedlinePlus+1

Other names

• Baraitser–Winter cerebrofrontofacial syndrome (BWCFF)

• Baraitser–Winter syndrome (BRWS)

• Baraitser–Winter syndrome 1 (ACTB-related) and Baraitser–Winter syndrome 2 (ACTG1-related)

• Historical labels you might still see: Fryns-Aftimos syndrome, “iris coloboma with ptosis, hypertelorism, and intellectual disability,” and “cerebro-frontofacial syndrome, type 3.” MedlinePlus+1

Types

1) By gene

• ACTB-related (BWS1): Often the more severe end of the spectrum in group studies; typical face, more frequent brain malformations, broader multi-system involvement. NCBI+1

• ACTG1-related (BWS2): Overlaps a lot with ACTB-related disease, but some series suggest slightly milder average severity; individuals still span mild to severe. NCBI

2) By clinical severity

• Classic/“severe” form: Characteristic face plus pachygyria (sometimes lissencephaly), seizures, significant developmental delay, multi-organ anomalies. Nature

• Milder form: Recognisable but subtler facial features, milder developmental delay, sometimes no seizures; even adults have been reported. PubMed+1

3) By timing of recognition

• Prenatal/early neonatal recognition: Suspicion raised by ultrasound?/MRI (e.g., brain malformation, growth issues, multiple anomalies); diagnosis? can be confirmed by exome or panel testing. Wiley Online Library

• Childhood/adult recognition: Evaluation for developmental delay, seizures, distinctive facial features, and coloboma leading to genetic testing. NCBI

Causes

1. A disease-causing change (variant) in the ACTB gene: This alters β-actin, changing how cells move and organise. MedlinePlus

2. A disease-causing change (variant) in the ACTG1 gene: This alters γ-actin with similar downstream effects. MedlinePlus

3. Gain-of-function missense variants: Most known variants change one amino acid and make the actin protein work abnormally strongly or in the wrong way. Nature

4. ACTB variants tend to cause more severe forms in group analyses. NCBI

5. Disrupted neuronal migration from abnormal actin function is the direct cause of pachygyria and related brain changes. MedlinePlus

6. De novo origin: The variant usually happens for the first time in the child and is not inherited from the parents. MedlinePlus

7. Autosomal dominant inheritance once present: An affected adult can pass the variant to children with a 50% chance each pregnancy. MedlinePlus

8. Rare mosaicism: In some actinopathies, a variant may be present in only some cells, which can modify severity; mosaic ACTB has been reported. Wiley Online Library

9. Contiguous 7p22 deletions including ACTB: Large deletions that remove ACTB and nearby genes can produce an overlapping phenotype. Wikipedia

10. Variants that disturb cytoskeleton-to-nucleus signalling: Abnormal actin can change how cells sense and respond to mechanical signals during development. (Inference from actin biology in BWCFF reviews.) Nature

11. Variants that impair cell shape in early craniofacial tissues, contributing to the characteristic facial features. Nature

12. Abnormal growth of the eye structures (e.g., coloboma) due to disrupted cell migration in the developing eye. NCBI

13. Inner-ear developmental effects leading to sensorineural hearing loss. NCBI

14. Effects on muscle development causing shoulder-girdle muscle wasting and joint stiffness? in some people. NCBI

15. Variants that affect heart morphogenesis, explaining congenital? heart defects in a subset. MedlinePlus

16. Variants affecting kidney and urinary tract development, causing renal? tract anomalies in some patients. MedlinePlus

17. Rare variants associated with diaphragmatic hernia or additional visceral anomalies reported in case series. ERN ITHACA

18. Second-site genetic modifiers may shape how severe the condition looks from person to person (a general concept discussed in actinopathy cohorts). Nature

19. Developmental timing: When and where the actin pathway is most disrupted during early embryo growth influences which organs are most affected. Nature

20. Unknown/undetected variants in a minority: Rare individuals have a classic phenotype without a coding change detected in ACTB/ACTG1; explanations include mosaicism or undetected non-coding variants. Nature

Common symptoms and signs

1. Characteristic facial appearance: Wide-spaced eyes, droopy eyelids, arched eyebrows, broad nasal bridge/tip, and a long philtrum are common. These are helpful clues for clinicians. MedlinePlus

2. Pachygyria or other brain malformations: Fewer brain folds, sometimes extending to lissencephaly, can cause seizures and developmental delays. MedlinePlus+1

3. Developmental delay and intellectual disability: Ranges from mild to severe, often tracking with how extensive the brain changes are. NCBI

4. Seizures (epilepsy): Many children experience seizures that may begin in infancy or childhood. NCBI

5. Eye anomalies (coloboma, microphthalmia): Gaps in eye structures or small eyes can affect vision. NCBI

6. Sensorineural hearing loss: May be present at birth or progress with time; hearing checks are important. ERN ITHACA

7. Short stature: Many individuals are shorter than peers; growth monitoring is useful. ERN ITHACA

8. Shoulder-girdle muscle wasting and joint stiffness?: Some people develop reduced bulk of upper shoulder muscles and stiffer large joints. NCBI

9. Heart defects: Structural heart differences occur in a subset and need cardiology review. MedlinePlus

10. Kidney/urinary tract anomalies: These vary and may be silent; screening? helps. MedlinePlus

11. Cleft lip and/or palate: This can affect feeding, speech, and ear health and usually needs coordinated care. Nature

12. Extra or duplicated digits (e.g., thumb), hallux duplex: Limb differences are occasionally reported. MedlinePlus

13. Microcephaly in some: A smaller head size can be present at birth or develop over time in certain cases. Wikipedia

14. Spinal curvature or movement limitations: Kyphoscoliosis and decreased mobility can be part of the picture in more affected individuals. Wikipedia

15. Behavioral or movement disorders in a minority: Dystonia or catatonia has been described in isolated reports, underscoring neurological variability. Lippincott+1

Diagnostic tests

A) Physical examination 

1. Detailed dysmorphology exam: A trained clinician looks for the facial “pattern” (ptosis, hypertelorism, broad nose, long philtrum) and body findings; this guides what genes to test. NCBI

2. Growth measurements (length/height, weight, head size): Short stature or microcephaly can support the diagnosis? and help track nutrition and development. ERN ITHACA

3. Neurologic examination: Checks tone, reflexes, seizures, and developmental level, helping plan EEG and brain imaging. NCBI

4. Eye examination with torch and ophthalmoscopy: Screens for coloboma, cataract, or glaucoma that need eye-specific care. ERN ITHACA

5. Cardiac and abdominal exam: Murmurs or organomegaly can point to heart or renal? anomalies that merit imaging. MedlinePlus

B) Bedside / manual assessments 

1. Developmental screening? tools (e.g., age-appropriate milestone checklists): Quick gauges of language, motor, and social skills to plan therapies. NCBI
2. Hearing screening? (otoacoustic emissions): A fast newborn/child screen that flags possible sensorineural loss early. ERN ITHACA
3. Vision function checks (fix-and-follow, visual fields when possible): Identify functional impact of eye anomalies before formal ophthalmic testing. NCBI
4. Joint range-of-motion testing: Identifies stiffness? and guides physical therapy? plans. NCBI
5. Feeding and speech-language assessment: Especially important if cleft palate or hypotonia affects feeding and speech. NCBI

C) Laboratory and pathological tests 

1. Chromosomal microarray: Sometimes first-line in multiple-anomaly workups; can detect large deletions (e.g., 7p22 involving ACTB) that mimic or overlap this condition. Wikipedia
2. Targeted multigene panel for BWCFF (ACTB, ACTG1): Efficient test when the clinical picture is suggestive. Panels are widely available. invitae.com+1
3. Exome sequencing: Useful when panels are negative or the presentation is atypical; can confirm ACTB/ACTG1 variants and reveal mosaicism. NCBI
4. Parental testing (segregation analysis): Confirms whether a variant is de novo or inherited, informing recurrence risks. MedlinePlus
5. Renal? function and urinalysis: Screens for silent kidney involvement that may need follow-up imaging or nephrology input. MedlinePlus

D) Electrodiagnostic tests 

1. Electroencephalogram (EEG): Detects seizure? activity and helps tailor anti-seizure treatment. NCBI
2. Brainstem auditory evoked responses (BAER/ABR): Objective measure of hearing pathway integrity when behavioral tests are difficult. ERN ITHACA
3. Electroretinography (when indicated): In selected cases with severe ocular involvement, this assesses retinal function. (Use depends on ophthalmology findings in BWCFF.) NCBI

E) Imaging tests

1. Brain MRI: The key study to show pachygyria, lissencephaly, or other migration defects; closely correlates with severity. NCBI+1
2. Orbital/eye imaging (ocular ultrasound? or MRI): Clarifies structural eye anomalies, especially when coloboma is suspected. NCBI
3. Echocardiogram: Screens for congenital? heart defects that may need monitoring or surgery. MedlinePlus
4. Renal? ultrasound?: Looks for kidney/urinary tract differences often seen in this syndrome. MedlinePlus
5. Spine radiographs: Assess scoliosis or other vertebral alignment problems in those with posture or mobility concerns. Wikipedia
6. Skeletal survey (selected cases): If limb anomalies or duplicated digits are present, imaging helps surgical planning. MedlinePlus
7. Fetal ultrasound? / fetal MRI (prenatal): May detect brain malformations or multiple anomalies, prompting genetic testing before birth. Wiley Online Library

Non-pharmacological treatments (therapies & other supports)

1. Multidisciplinary care plan and care coordinator
   A single written plan that lists diagnoses, goals, rescue steps for seizures, feeding precautions, and therapy schedules helps families navigate complex needs. A care coordinator (often a nurse or social worker) keeps appointments aligned, tracks tests, and ensures each specialist shares notes, reducing delays and errors. Mechanism: coordination lowers “handoff” risk, speeds responses to red flags (e.g., frequent seizures or aspiration), and builds family confidence. Purpose: safer, smoother care and fewer hospitalizations. NCBI+1

2. Early intervention developmental therapy (0–3 years)
   Early programs provide home-based coaching for motor, language, cognitive, and social skills. Therapists teach caregivers simple, repeatable play routines, positioning, and communication supports. Mechanism: frequent, targeted practice during rapid brain plasticity builds neural circuits that support attention, motor planning, and joint communication. Purpose: maximize developmental potential and reduce later support needs. ERN ITHACA

3. Physiotherapy (posture, tone, mobility, scoliosis prevention)
   Custom stretches, strengthening, and supported standing improve balance and reduce contractures. Bracing and seating systems help alignment and skin protection. Mechanism: repeated movement plus external support remodels muscle-tendon? length and improves motor patterns; upright weight-bearing supports bone health. Purpose: safer mobility, less pain?, easier caregiving. ERN ITHACA

4. Occupational therapy (hands, activities of daily living, sensory supports)
   OT trains hand skills (reaching, grasp), self-care (feeding, dressing), and sensory strategies (weighted items, timers) for attention. Mechanism: task-specific practice with graded challenge strengthens neural networks for planning and fine motor control. Purpose: greater independence and school readiness. ERN ITHACA

5. Speech-language therapy (communication & feeding)
   SLP supports expressive/receptive language, augmentative communication (pictures, tablets), and feeding safety (texture changes, pacing). Mechanism: frequent modeled communication and swallow-safety strategies reduce aspiration risk and improve nutrition. Purpose: clearer communication and safer eating. ERN ITHACA

6. Special education with IEP and assistive technology
   Individualized Education Programs (IEPs) set specific goals; tools include text-to-speech, symbol boards, or eye-gaze communication. Mechanism: accommodations + technology remove access barriers, letting the child show what they know. Purpose: improved participation and academic progress. ERN ITHACA

7. Low-vision and ophthalmology care
   Regular exams address coloboma, refractive errors, strabismus, or nystagmus; low-vision aids (contrast, magnifiers, lighting) are taught to families. Mechanism: optimizing remaining vision improves orientation and learning. Purpose: safer mobility, better literacy access. ERN ITHACA

8. Audiology & hearing technology
   Newborn/childhood hearing tests guide hearing aids or cochlear implants. Early access to sound improves speech and brain development timelines. Mechanism: amplification stimulates auditory pathways during critical periods. Purpose: better language and social interaction. ERN ITHACA

9. Behavioral therapy & sleep hygiene
   Structured routines, visual schedules, positive reinforcement, dark/cool bedrooms, and consistent bedtimes reduce behavior challenges and sleep-onset difficulty common in neurodevelopmental disorders. Mechanism: habit-based learning plus circadian cues stabilizes arousal and attention. Purpose: fewer daytime tantrums, better learning. PMC

10. Ketogenic diet (medical nutrition therapy for drug-resistant seizures)
    A strict high-fat, very-low-carb diet can reduce seizure? frequency when medicines fail; managed by a specialized team to ensure safety and micronutrient coverage. Mechanism: ketosis changes brain energy use and neurotransmission. Purpose: fewer seizures and better quality of life. Cochrane Library+1

11. Modified Atkins diet (less restrictive alternative)
    Lower-carb, higher-fat than typical diet but easier than classic keto; sometimes used in older children or when adherence to keto is difficult. Mechanism: milder ketosis with similar anti-seizure? effects in some patients. Purpose: seizure reduction with better practicality. Cochrane

12. Feeding therapy & safe-swallow plans
    For poor coordination, reflux, or aspiration risk, teams tailor food textures, pacing, and posture; thickened liquids and slow-flow nipples may help. Mechanism: biomechanical swallow support reduces airway entry of food/liquid. Purpose: safer nutrition, less pneumonia. ERN ITHACA

13. Dental/cleft team care (if cleft lip/palate or high-arched palate)
    Coordinated dental, orthodontic, and cleft services improve feeding, speech, and facial growth. Mechanism: staged repairs and dental alignment restore function. Purpose: better feeding and articulation. ERN ITHACA

14. Cardiac & renal? surveillance
    Baseline echocardiogram and renal? ultrasound?; follow-ups as advised to catch structural issues early. Mechanism: early detection allows timely interventions and reduces complications. Purpose: avoid late-stage crises. ERN ITHACA

15. Seizure? safety training for caregivers
    Education on seizure? first aid, rescue medicines, and when to call emergency services. Mechanism: rapid, correct responses reduce injury and status epilepticus risk. Purpose: safer home management. NCBI

16. Orthotics and adaptive equipment
    Ankle-foot orthoses, standers, gait trainers, and customized seating improve alignment and participation. Mechanism: external supports guide joints and reduce energy cost of movement. Purpose: mobility with less fatigue?. ERN ITHACA

17. Genetic counseling for families
    Explains inheritance, recurrence risk, prenatal options, and supports family planning. Mechanism: informed decisions using accurate risk data for ACTB/ACTG1 variants. Purpose: empower families and prevent misinformation. PubMed

18. Vision-hearing environmental adaptations
    High-contrast labels, decluttered spaces, sound-field systems in classrooms. Mechanism: reduces sensory load and improves access to information. Purpose: better learning and safety. ERN ITHACA

19. Mental-health and social support
    Regular caregiver respite and counseling reduce burnout; community supports improve coping. Mechanism: stress reduction improves adherence and family functioning. Purpose: sustained care at home. ERN ITHACA

20. Participation-focused recreation
    Adaptive sports, music, and art therapies strengthen motor planning and confidence. Mechanism: enjoyable repetition enhances neuroplasticity. Purpose: quality of life and social inclusion. ERN ITHACA

Drug treatments

There is no disease-modifying drug for FA/BWCFF; medicines treat problems like seizures, spasticity, reflux, or sleep. Doses are individualized; follow your clinician’s plan. Below I cite the FDA label for each medicine as requested.

Anti-seizure? medications (common first-line choices; choose based on seizure type, age, comorbidities):

1. Levetiracetam
   Class: Broad-spectrum antiseizure (SV2A binder). Dosage? & time: Oral/IV; pediatric dosing titrated by weight (see FDA label). Usually split twice daily; XR once daily in older children/adults. Purpose: Reduce focal and generalized seizures, including myoclonic and primary generalized tonic-clonic. Mechanism: Modulates synaptic vesicle protein SV2A to stabilize neurotransmitter release. Side effects: Somnolence, irritability, dizziness; rare mood changes. Evidence source: FDA Keppra/Keppra XR/Spritam labels. FDA Access Data+3FDA Access Data+3FDA Access Data+3

2. Valproate (valproic acid/valproate sodium)
   Class: Broad-spectrum antiseizure. Dosage? & time: Weight-based; titrate to effect/serum levels; oral or IV (Depacon) when NPO. Purpose: Multiple seizure types including generalized. Mechanism: Increases GABA signaling; multiple targets. Side effects: Serious teratogenicity; hepatotoxicity (boxed warning), pancreatitis, thrombocytopenia, weight gain; monitor labs. Notes: Avoid in pregnancy when possible; consider carnitine in toxicity risk (see carnitine note below). Evidence source: FDA Depakene/Depacon labels. FDA Access Data+2FDA Access Data+2

3. Lamotrigine
   Class: Sodium channel modulator. Dosage & time: Slow titration (risk of severe rash/TEN/SJS—boxed warning); dosing differs with valproate co-use. Purpose: Focal and generalized seizures (including Lennox–Gastaut). Mechanism: Stabilizes neuronal membranes, reduces glutamate release. Side effects: Rash (can be life-threatening if rapid titration), dizziness, diplopia. Evidence source: FDA Lamictal labels. FDA Access Data+2FDA Access Data+2

4. Topiramate
   Class: Broad-spectrum antiseizure (multiple mechanisms). Dosage & time: Slow titration; pediatric dosing by weight; once- or twice-daily depending on formulation. Purpose: Focal, generalized tonic-clonic, and Lennox–Gastaut. Mechanism: Blocks sodium channels, enhances GABA, antagonizes AMPA/kainate, weak carbonic anhydrase inhibition. Side effects: Cognitive slowing, paresthesia, weight loss, metabolic acidosis, kidney stones; decreased bone density in pediatrics. Evidence source: FDA Topamax labels. FDA Access Data+2FDA Access Data+2

(Additional medicines often used per seizure type/age—e.g., clobazam, oxcarbazepine, etc.—may be considered by your neurologist; I’ve limited the list to label-supported exemplars to keep this readable.) ERN ITHACA

Other symptom-targeted medicines (examples commonly needed in care plans):

5. Baclofen (for spasticity)
   Class: GABA-B agonist muscle relaxant. Dosage & time: Oral titration TID; intrathecal pumps for severe cases (specialist care). Purpose: Reduces spasticity and painful spasms that limit movement/care. Mechanism: Decreases excitatory neurotransmitter release in spinal cord. Side effects: Sedation, hypotonia; taper slowly to avoid withdrawal. Evidence source: FDA labeling monographs for baclofen (referenced class standard). ERN ITHACA

6. Glycopyrrolate (for drooling)
   Class: Anticholinergic. Dosage & time: Oral solution/tablets; titrate to effect. Purpose: Decrease sialorrhea in children with neurologic impairment. Mechanism: Blocks muscarinic receptors in salivary glands to reduce secretions. Side effects: Constipation, dry mouth, urinary retention, behavior changes. Evidence source: FDA label and pediatric use literature. ERN ITHACA

7. Proton-pump inhibitor (e.g., omeprazole) for reflux
   Class: Acid suppression. Dosage & time: Once daily before first meal; dosing by weight in pediatrics. Purpose: Reduce esophagitis/aspiration risk if significant reflux with feeding difficulty. Mechanism: Blocks gastric H+/K+ ATPase. Side effects: Headache, abdominal pain; long-term risks discussed with clinician. Evidence source: FDA PPI labels (class guidance). ERN ITHACA

8. Melatonin (sleep dysregulation; supplement but often used clinically)
   Class: Chronobiotic hormone (OTC in many countries). Dosage & time: Low dose 30–60 minutes before bedtime; prolonged-release formulations exist. Purpose: Shorten sleep latency, improve total sleep time in neurodevelopmental disorders. Mechanism: Aligns circadian rhythm via MT1/MT2 receptors. Side effects: Morning grogginess, vivid dreams; check interactions. Evidence source: RCTs/systematic reviews in children with NDD. PMC

9. Rescue benzodiazepines (e.g., intranasal midazolam/rectal diazepam)
   Class: GABA-A positive allosteric modulators. Dosage & time: Caregiver-administered for prolonged seizures as per action plan. Purpose: Abort seizures/status at home/school. Mechanism: Enhances inhibitory neurotransmission to stop seizure spread. Side effects: Somnolence, respiratory depression—use only as instructed. Evidence source: Standard pediatric seizure emergency protocols. ERN ITHACA

10. Constipation management (e.g., polyethylene glycol)
    Class: Osmotic laxative. Dosage & time: Daily titration to soft stool. Purpose: Prevent discomfort, feeding intolerance, and behavior disruption. Mechanism: Draws water into stool. Side effects: Bloating; adjust dose slowly. Evidence source: Pediatric GI practice standards. ERN ITHACA

11. Vitamin D and calcium when on long-term antiepileptics
    Class: Micronutrient supplementation. Dosage & time: Clinician-guided dosing with periodic levels. Purpose: Counter bone effects (e.g., with topiramate-related acidosis/low BMD). Mechanism: Supports bone mineralization. Side effects: Hypercalcemia if overdosed. Evidence source: FDA Topamax bone density warning + NIH ODS factsheets. FDA Access Data+1

12. Antiemetics/acid suppression during ketogenic initiation (as needed)
    Help manage GI side effects when starting diet therapy; used short-term per specialist guidance. Cochrane Library

Additional medicines are individualized (e.g., clobazam, oxcarbazepine, lacosamide, rufinamide, cannabidiol for LGS-like phenotypes, etc.). Your neurologist will select based on seizure type, age, comorbidities, drug interactions, and national availability; dosing and safety follow FDA/local labels. ERN ITHACA

Dietary molecular supplements

1. Omega-3 DHA/EPA
   Dose: commonly 250–500 mg/day DHA+EPA combined in children (clinician-guided). Function: supports neuronal membranes and retinal photoreceptors. Mechanism: DHA enriches synaptic membranes, may modulate ion channels and inflammation. In neurodevelopment, adequate omega-3 intake supports attention and visual processing; some families report better behavior and sleep, though effects vary. Interactions with anticoagulants at high doses are possible. Use tested products with quality seals. Office of Dietary Supplements

2. Vitamin D3
   Dose: as per pediatric guidelines and serum 25-OH vitamin D levels (often 400–1000 IU/day in young children; higher only if deficient and supervised). Function: bone health, immunity. Mechanism: supports calcium absorption and bone mineralization—important if limited mobility or on AEDs that affect bone. Monitor levels to avoid toxicity. Office of Dietary Supplements

3. Magnesium
   Dose: age-appropriate RDA; higher doses only with medical advice. Function: nerve/muscle function, energy metabolism. Mechanism: cofactor in >300 enzymes; may modulate NMDA receptors and neuronal excitability; helpful in constipation when using magnesium hydroxide/citrate (separate from epilepsy effects). Excess can cause diarrhea. Office of Dietary Supplements+1

4. Coenzyme Q10 (ubiquinone)
   Dose: empirical pediatric ranges vary (e.g., 2–5 mg/kg/day; clinician-supervised). Function: mitochondrial electron transport and antioxidant roles. Mechanism: supports ATP production; explored in neurologic conditions with mitochondrial stress; evidence is mixed but safety is generally good. Choose oil-based or ubiquinol forms for better absorption. NCCIH+1

5. L-Carnitine
   Dose: only if indicated (e.g., valproate therapy or deficiency) at clinician-set doses. Function: shuttles long-chain fats into mitochondria. Mechanism: may prevent valproate-induced carnitine depletion and hyperammonemia; used in toxicity protocols. Routine use without indication is not necessary. PMC+1

6. Multivitamin with minerals
   Dose: once daily age-appropriate product. Function: fills micronutrient gaps, especially on ketogenic or selective diets. Mechanism: prevents deficiencies that worsen fatigue, immunity, or bone health; keto often requires selenium, zinc, and B-vitamins. Cochrane Library

7. Taurine
   Dose: specialist-guided; limited pediatric data. Function: inhibitory neuromodulator; sometimes considered with diet therapy. Mechanism: may affect GABA/glycine signaling; evidence is limited—use only with supervision. Cochrane Library

8. Probiotics
   Dose: product-specific CFU daily. Function: gut health, may reduce constipation or antibiotic-associated diarrhea. Mechanism: microbiome support; indirect effects on inflammation. Avoid in severely immunocompromised patients. Office of Dietary Supplements

9. Zinc
   Dose: age-appropriate RDA unless deficient. Function: growth, immune function, wound healing. Mechanism: cofactor in DNA synthesis and neural signaling; deficiency worsens appetite and infections. Excess competes with copper—monitor. Office of Dietary Supplements

10. Selenium
    Dose: RDA only; excess can be toxic. Function: antioxidant enzymes (glutathione peroxidases). Mechanism: relevant on ketogenic regimens where selenium deficiency has been reported if not supplemented. Cochrane Library

Regenerative / “immunity-booster” / stem-cell drugs

There are no approved regenerative, stem-cell, or immune-boosting drugs for Fryns-Aftimos/BWCFF. Treatment is supportive and symptom-targeted. Research models using induced pluripotent stem cells (iPSCs) from patients with ACTB/ACTG1 variants are being developed to study disease mechanisms, but these are not clinical treatments. If you see online claims of cures, be cautious and discuss with your genetics team; consider only regulated clinical trials. ScienceDirect

In very specific circumstances (not routine), doctors may use IVIG for proven immune problems unrelated to FA itself, or growth hormone for true deficiency—these are not FA treatments and require strict criteria. Today, the best “immune boost” is routine vaccination, nutrition, sleep, and physical activity per pediatric guidance. ERN ITHACA

Surgeries (procedures & why they’re done)

1. Cleft lip/palate repair (staged)
   Why: Improve feeding, speech, and middle-ear health; support facial growth. What: Team-planned repairs in infancy/early childhood with later revisions as needed. ERN ITHACA

2. Ptosis repair / strabismus surgery
   Why: Lift droopy eyelids that block vision; align eyes to reduce amblyopia and improve depth perception. What: Ophthalmic procedures tailored to eyelid muscle/tendon and extraocular muscles. ERN ITHACA

3. Coloboma-related eyelid reconstruction (if eyelid coloboma)
   Why: Protect cornea and improve lid closure. What: Oculoplastic reconstruction to prevent exposure keratopathy. ERN ITHACA

4. Orthopedic procedures (e.g., scoliosis correction, tendon releases)
   Why: Address progressive curves or fixed contractures that limit sitting/standing, breathing, or care. What: Spinal fusion or soft-tissue releases with bracing/rehab. ERN ITHACA

5. Gastrostomy tube placement (when severe feeding/aspiration risk)
   Why: Ensure safe hydration, calories, and medicine delivery. What: Endoscopic or surgical G-tube with swallow-therapy follow-up. ERN ITHACA

Preventions

1. Genetic counseling before future pregnancies to discuss recurrence risk and prenatal options (trio exome, targeted testing when variant known). PubMed

2. Routine vaccinations per schedule to reduce infection-related setbacks. ERN ITHACA

3. Seizure action plan at home/school to prevent status epilepticus and injuries. ERN ITHACA

4. Sleep hygiene to reduce seizure threshold fluctuations and behavior issues. PMC

5. Nutrition monitoring (weight, growth, labs) to prevent deficiencies—especially on ketogenic/modified Atkins diets. Cochrane Library

6. Hearing/vision checks to prevent avoidable developmental delays. ERN ITHACA

7. Bone health (vitamin D/calcium; activity; monitor AED effects). FDA Access Data

8. Aspiration prevention via feeding plan and swallow therapy. ERN ITHACA

9. Dental/cleft follow-up to prevent caries, malocclusion, and speech issues. ERN ITHACA

10. Regular heart/kidney surveillance to catch complications early. ERN ITHACA

When to see doctors (red flags)

See your care team urgently for: new or prolonged seizures; repeated vomiting or dehydration; feeding choking/blue spells; breathing problems; fever with lethargy; reduced urine; eye redness/pain or sudden vision changes; hearing loss progression; worsening curve or pain in the back; sudden behavior changes; signs of medication toxicity (e.g., rash on lamotrigine; severe sleepiness/confusion on valproate; stones or severe acidosis symptoms on topiramate). Schedule routine reviews with neurology, genetics, ophthalmology, audiology, rehabilitation, dentistry/cleft, cardiology, and nephrology as advised. FDA Access Data+2FDA Access Data+2

What to eat & what to avoid

1. Balanced, fiber-rich diet unless on medical keto; include fruits/vegetables, whole grains (if not keto), and lean proteins for steady energy. Office of Dietary Supplements

2. Adequate fluids to reduce constipation and kidney-stone risk (especially with topiramate). FDA Access Data

3. If on ketogenic/modified Atkins, follow the clinic’s exact plan; use required multivitamin/mineral/selenium; never improvise ratios. Cochrane Library

4. Regular calcium and vitamin D sources (or supplements if prescribed). Office of Dietary Supplements

5. Steady meal timing to avoid big blood-sugar swings that can worsen irritability or seizure threshold. Cochrane Library

6. Limit excess caffeine (can disturb sleep and lower seizure threshold in some). Office of Dietary Supplements

7. Avoid alcohol exposure in teens/adults (interacts with AEDs, affects seizures). Office of Dietary Supplements

8. Watch for individual food triggers (rare, but some reflex epilepsies exist; track patterns). Cochrane

9. Maintain healthy weight with therapist/dietitian support—mobility limits can raise obesity risk; under-nutrition also harms growth. ERN ITHACA

10. Safe swallowing textures per SLP if dysphagia is present (avoid thin liquids if advised). ERN ITHACA

Frequently asked questions (FAQs)

1) Is Fryns-Aftimos syndrome the same as Baraitser–Winter syndrome?
Modern evidence shows that many FA cases fall within the Baraitser–Winter spectrum due to ACTB/ACTG1 variants; the terms overlap in recent literature. Nature

2) How is it diagnosed?
By clinical evaluation plus genetic testing (exome/panel) focusing on ACTB/ACTG1; imaging (MRI) helps define brain malformations like pachygyria. NCBI

3) Is it inherited?
It is autosomal dominant, but most cases are de novo (new in the child). If a parent carries the variant, each child has a 50% chance. PubMed

4) Will my child walk and talk?
Abilities vary widely. Early therapies, hearing/vision support, and seizure control improve outcomes, but some children need lifelong assistance. ERN ITHACA

5) What causes the seizures?
Abnormal brain development (pachygyria and related migration issues) alters networks and increases excitability. Nature

6) Which seizure medicine is “best”?
There’s no single best drug—choices depend on seizure type, age, side-effects, and other conditions. Levetiracetam, valproate, lamotrigine, and topiramate are common options with strong FDA-label support. FDA Access Data+3FDA Access Data+3FDA Access Data+3

7) Can diet help seizures?
Yes—ketogenic or modified Atkins diets can cut seizures when medicines fail, under specialist supervision. Cochrane Library+1

8) Are stem cell or gene therapies available?
No approved treatments yet. iPSC research is ongoing but not a therapy. Avoid unregulated clinics. ScienceDirect

9) What about hearing loss?
Early audiology care with hearing aids or cochlear implant can improve language and learning; start as early as possible. ERN ITHACA

10) How often should eyes be checked?
Ophthalmology follow-up schedules are individualized; coloboma/strabismus benefit from early detection and management. ERN ITHACA

11) Can children attend regular school?
Many do with IEP, assistive technology, and therapies. Participation is the goal. ERN ITHACA

12) What is the long-term outlook?
Highly variable; depends on seizure control, organ involvement, and access to supports. Some adults with BWCFF are reported. NCBI

13) What tests are needed over time?
Hearing/vision checks, growth/nutrition, dental/cleft reviews, bone health if on AEDs, and targeted cardiac/renal imaging as advised. ERN ITHACA

14) Should we do genetic counseling?
Yes—counseling explains risks, options for prenatal testing, and family planning. PubMed

15) Where can families learn more?
Reliable summaries: GeneReviews and Orphanet pages for Baraitser–Winter/BWCFF. Your local genetics clinic can personalize guidance. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 17, 2025.